Physician profile
Casey Fu
NPI 1558570887
$45,356.34
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $3,358 · 2021: $13K · 2022: $13K · 2023: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $30,884.77 | 2019-2023 | |
| Abbvie INC. | $5,521.77 | 2019-2023 | |
| Janssen Biotech, INC. | $2,042.48 | 2019-2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,495.46 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $1,121.75 | 2019-2023 | Entyvio |
| Janssen Scientific Affairs, LLC | $609.22 | 2019-2022 | |
| Redhill Biopharma INC. | $434.56 | 2020-2023 | Aemcolo, Talicia, Movantik |
| Qol Medical, LLC | $432.89 | 2019-2023 | Sucraid |
| Merck Sharp & Dohme LLC | $425.37 | 2019-2023 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $343.68 | 2021-2022 | |
| Pfizer INC. | $334.06 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $226.36 | 2019-2022 | |
| Ardelyx, INC. | $201.04 | 2022 | |
| Celgene Corporation | $198.34 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $188.33 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $123.63 | 2019 | |
| Genzyme Corporation | $87.21 | 2022 | |
| Allergan, INC. | $86.12 | 2019-2020 | |
| Endogastric Solutions, INC | $80.40 | 2019 | |
| Erbe USA INC | $74.21 | 2019 | |
| Nestle Healthcare Nutrition INC. | $70.44 | 2021 | |
| Braintree Laboratories, INC. | $60.98 | 2019-2021 | |
| Vivus LLC | $53.25 | 2019 | |
| Covidien Lp | $50.85 | 2019 | |
| Alfasigma USA, INC. | $47.56 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $46.81 | 2023 | Dupixent |
| Shionogi INC | $25.97 | 2020 | |
| Medtronic, INC. | $25.35 | 2021 | |
| Concordia Pharmaceuticals INC. | $22.94 | 2019 | |
| Evoke Pharma, INC. | $21.38 | 2022 | |
| Shire North American Group INC | $19.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.